- Home
- MDGL
as 09-18-2025 4:00pm EST
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WEST CONSHOHOCKEN |
| Market Cap: | 6.1B | IPO Year: | N/A |
| Target Price: | $474.67 | AVG Volume (30 days): | 341.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $200.63 - $457.16 | Next Earning Date: | 10-30-2025 |
| Revenue: | $515,547,000 | Revenue Growth: | 3421.98% |
| Revenue Growth (this year): | 394.12% | Revenue Growth (next year): | 57.74% |
Stock Insider Trading Activity of Madrigal Pharmaceuticals Inc. (MDGL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sibold William John | MDGL | President and CEO | Sep 9 '25 | Sell | $445.63 | 7,279 | $3,243,740.77 | 102,474 | |
| Sibold William John | MDGL | President and CEO | Aug 21 '25 | Sell | $400.52 | 7,616 | $3,047,756.37 | 102,474 | |
| BAKER BROS. ADVISORS LP | MDGL | N/A | Aug 20 '25 | Buy | $384.95 | 59,901 | $23,071,366.47 | 1,913,699 | |
| BAKER BROS. ADVISORS LP | MDGL | N/A | Aug 18 '25 | Buy | $364.61 | 105,782 | $38,849,657.82 | 1,913,699 | |
| Kelley Shannon T | MDGL | General Counsel | Aug 18 '25 | Sell | $371.08 | 1,304 | $479,626.86 | 9,809 | |
| BATE KENNETH | MDGL | N/A | Aug 15 '25 | Sell | $365.88 | 10,000 | $3,652,008.56 | 4,627 | |
| FRIEDMAN PAUL A | MDGL | N/A | Aug 13 '25 | Sell | $366.29 | 129,172 | $47,825,149.36 | 307,935 | |
| Taub Rebecca | MDGL | N/A | Aug 12 '25 | Sell | $355.31 | 43,263 | $15,388,278.50 | 492,095 | |
| FRIEDMAN PAUL A | MDGL | N/A | Aug 12 '25 | Sell | $355.37 | 43,605 | $15,509,469.03 | 307,935 | |
| Taub Rebecca | MDGL | N/A | Aug 11 '25 | Sell | $350.60 | 3,200 | $1,120,753.15 | 492,095 |
Latest Madrigal Pharmaceuticals Inc. News
MDGL Breaking Stock News: Dive into MDGL Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Madrigal Pharmaceuticals Insider Sold Shares Worth $3,047,756, According to a Recent SEC Filing
GlobeNewswire
a month ago
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
Madrigal Pharmaceuticals Wins EU Approval for Rezdiffra
GlobeNewswire
a month ago
Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
Insider Monkey
3 months ago
Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra
Pharmaceutical Technology
3 months ago
Madrigal poised to enter European MASH market after CHMP endorsement
MT Newswires
3 months ago
Sector Update: Health Care Stocks Rise Premarket Friday
MT Newswires
3 months ago
Exchange-Traded Funds Slightly Higher, Equity Futures Mixed Pre-Bell Friday as Geopolitical, Trade Risks Mount
Compare MDGL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MDGL Madrigal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.